Amneal Receives FDA Approval for IPX203 in Parkinson’s Disease, to be Launched as CREXONT® (carbidopa and levodopa) Extended-Release Capsules
Amneal Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved CREXONT® (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease (PD). CREXONT is a novel oral formulation of carbidopa/levodopa (CD/LD) that combines both immediate-release (IR) granules and extended-release (ER) granules. Existing oral immediate-release CD/LD products have a short duration … Read more